Sen. Joe Manchin Joseph (Joe) ManchinNames to watch as Trump picks Ginsburg replacement on Supreme Court Momentum growing among Republicans for Supreme Court vote before Election Day Gardner on court vacancy: Country needs to mourn Ginsburg 'before the politics begin' MORE's (D-W.Va.) daughter may have to explain to Congress why her company hiked up the price of EpiPens, Bloomberg News is reporting.

Heather Bresch serves as the CEO of Mylan, which acquired EpiPen in 2007. Since then, the device's cost has increased 400 percent, from $57 to more than $500.

Bresch could be called to Capitol Hill next month to explain the price increase, according to Bloomberg.

ADVERTISEMENT

Members of Congress have expressed concern over the price increase for the EpiPen, a lifesaving injection for people suffering from severe allergic reactions.

“I am deeply concerned by this significant price increase for a product that has been on the market for more than three decades, and by Mylan’s failure to publicly explain the recent cost increase, which places a significant burden on parents, schools and other purchasers of the EpiPen,” Sen. Mark Warner Mark Robert WarnerIntelligence chief says Congress will get some in-person election security briefings Overnight Defense: Trump hosts Israel, UAE, Bahrain for historic signing l Air Force reveals it secretly built and flew new fighter jet l Coronavirus creates delay in Pentagon research for alternative to 'forever chemicals' House approves bill to secure internet-connected federal devices against cyber threats MORE (D-Va.) said Tuesday in a statement.

In a letter Monday, Sen. Richard Blumenthal (D-Conn.), a member of the Senate Judiciary Committee, asked Bresch to explain the "shocking price increases."

He declined during an interview on Tuesday to comment about the possibility that Bresch would come before Congress.

Rep. Grace Meng (D-N.Y.), meanwhile, is calling for a full committee hearing on the cost of EpiPens. In a letter to the chairman and ranking member of the House Oversight and Government Reform Committee on Monday, Meng relayed her concerns over the drug price hike.

As of Tuesday afternoon, no hearing was scheduled on the issue, a spokeswoman for committee Chairman Jason Chaffetz Jason ChaffetzThe myth of the conservative bestseller Elijah Cummings, Democratic chairman and powerful Trump critic, dies at 68 House Oversight panel demands DeVos turn over personal email records MORE told Bloomberg. The spokeswoman offered no comment beyond that.

Elijah Cummings, the top Democrat on the Oversight Committee, called the price hike a "financial burden on those who desperately need this drug" and expressed a desire for "an investigation of this issue and for the Committee to hold a hearing in September."